PACKAGE LEAFLET FOR USE
Tobraculin-D eye drops, suspension for dogs and cats
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER, IF DIFFERENT NAME OF THE VETERINARY MEDICINAL PRODUCT
Tobraculin-D eye drops, suspension for dogs and cats
STATEMENT SUBSTANCE(S) INGREDIENT(S)
1 ml of the suspension contains 3 mg of tobramycin (as sulphate) and 1 mg of
Excipients: benzalkonium chloride, disodium edetate, potassium dihydrogen phosphate,
disodium phosphate dodecahydrate, sodium chloride, polysorbate 80, hydroxyethylcellulose,
INDICATIONS
The product is used in inflammatory conditions of the conjunctiva, cornea and anterior
chamber of the eye, where the use of corticosteroids is recommended and there is a risk of or
an existing superficial bacterial infection – conjunctivitis, keratitis, keratoconjunctivitis,
blepharitis, blepharoconjunctivitis, hordeolum, dacrocystitis, iritis, after extraction of foreign
bodies from the cornea and conjunctiva; preoperatively and postoperatively, in extra- and
intrabulbar operations in dogs and cats.
CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substances or to any of the excipients. Do
not use in viral and fungal infections of the eyes. Do not use other eye drops or ointments
ADVERSE REACTIONS
Serious adverse effects from the use of Tobraculin-D have not been observed. Burning,
itching and swelling of the eyelids, photophobia or conjunctival erythema are likely to occur.
In such cases, the administration of the product should be discontinued.
With prolonged use of the product, disbacteriosis with overgrowth of microorganisms, non-
susceptible to tobramycin, including fungi, is likely to occur. In such cases, appropriate
treatment should be instituted. Delayed healing of ocular defects and an increase of the
If you notice any serious effects or other effects resulting from the use of this veterinary
medicinal product, not mentioned in this package leaflet, please inform immediately your
TARGET SPECIES SPECIES, ROUTE(S) ADMINISTRATION Method of administration:
Shake the vial vigorously before use. Apply by instilling into the lower conjunctival sac,
taking care to avoid the contact betwen the dropper applicator and the eye and the skin of the
hands. After each instillation, the inner corner of the eye is pressed for about 30-60 seconds,
in order to prevent a leakage of the suspension through the lacrimal ducts.
Usually, 1-2 drops are instilled every 4-6 hours. In acute inflammation, the treatment can be
initiated with 1-2 drops every 2 hours for the first 24-48 hours, and gradually, along with
improvement of the clinical symptoms, be switched to a regime of 1-2 drops every 4-6 hours.
ADVICE ON CORRECT ADMINISTRATION
When handling the product, care should be taken for contamination of the skin of the hands,
10. WITHDRAWAL PERIOD 11. SPECIAL STORAGE PRECAUTIONS
Store in a dry place. Protect from direct sunlight.
Shelf-life after first opening the vial: 28 days at a temperature below 25° С.
12. SPECIAL WARNING(S) 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary
medicinal product should be disposed of in accordance with local requirements.
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 15. OTHER INFORMATION
White plastic vials containing 5 ml, fitted with a dropper applicator and closed with a screw
Dr. rer. nat. Frank GollnickForschungsgemeinschaft FunkJuutilainen, 1997: Juutilainen J, Lang S: “Genotoxic, carcinogenic and teratogenic effects of electromagnetic fields. Introduction and overview” in: Mutat Res 1997; 387 (3): 165 - 171Brusick, 1998: Brusick D, Albertini R, Mc Ree D, Peterson D, Williams G, Hanawalt P, Preston J: “Genotoxicity of radiofrequency radiation. DNA/Genetox Exp
Product Name ANFITECH BIOTIN Synthetic Antibody Aptamer specific for Rat Brain Tumor Microvessels Concentration 2 mg/ml Synonymns High affinity Oligonucleotide specific for Rat Brain Tumor Microvessels Background Neoangiogenesis, the new formation of blood vessels is associated with endothelial cell proliferation, migration, and formation of new capillaries as a response to t